Fibrin sponge
AssigneesBaxter Aktiengesellschaft, Baxter International Inc.
InventorsThomas Seelich, Edgar Scheel, Johann Odar, Yves Alain Delmotte
Life of this patent
Estimating the term…
Abstract
The invention relates to a fibrin sponge comprising a residual moisture content of at least 3%, preferably of 3 to 35%, in particular 10 to 20%, and preferably containing a blood clotting activator or proactivator, a method of preparing this fibrin sponge as well as a kit for wound gluing which comprises the fibrin sponge and a component containing a blood clotting factor. The sponge according to the present invention is suitable for hemostasis, tissue adhesion and aiding wound healing.
Claims42
A storage-stable fibrin sponge comprising a residual moisture of at least 10%.
A kit for wound coverage, said kit comprising a storage-stable fibrin sponge having a residual moisture of at least 10% and a component containing a blood clotting factor.
A method of preparing a fibrin sponge, said method comprising
- preparing a fibrin clot by mixing a fibrinogen solution with a thrombin solution and incubating the resulting mixed solution at a certain temperature for a period of time sufficient for formation of said fibrin clot,
- b) deep-freezing and lyophilizing said fibrin clot, and
- c) adjusting a residual moisture in said fibrin clot to at least 10%.
A method of treating a patient suffering from wounds and hemorrhages, said method comprising applying to said patient a fibrin sponge having a residual moisture of at least 10%, for at least one of hemostasis, tissue adhesion, cell culture supported healing and wound healing.
A kit comprising a storage-stable fibrin sponge having a residual moisture of at least 10% is sterile form for use as a biological support for cell cultures.
Dependencies are inferred from the claim text.